Mindbloom Releases First America on Psychedelics Report

Findings confirm psychedelic medicine is moving into the mainstream of mental health — and more people have tried it than you think. Download the full report here.

‍

Five years ago, many Americans had never heard of psychedelic medicine – and if they had, the phrase conjured up caricatures from too many bad movies. Psychedelics were vilified by the War on Drugs, and the idea that they could become a mainstream mental health treatment seemed like science fiction. 

Today, that view has been turned on its head, and psychedelic medicine is at the center of the mental health conversation. At Mindbloom, we hear stories every day from clients whose lives have been positively transformed by psychedelic medicine. We see representatives in Congress proposing legislation on psychedelic research, and we read about professional athletes using psychedelics to improve their mental health. 

With all this public discussion, we wanted to understand better what mental health challenges Americans are facing, and how they view psychedelic medicine. So we surveyed a nationally representative sample of people across the U.S., and the America on Psychedelics report released today presents a surprising – and encouraging – picture of Americans’ embrace of psychedelic medicine. 

Highlights include:

• 58% of Americans are open to trying ketamine therapy or other psychedelic medicine
• … and 25% would prefer ketamine therapy to antidepressants or talk therapy‍
• Black Americans are 2x as likely as White Americans to have received psychedelic therapy
• Millennials are 13x as likely as Gen X or Baby Boomers to have received ketamine therapy
• Men are more than 2.5x as likely as women to have received ketamine therapy or other psychedelic medicine

The challenge of ending the mental health crisis is daunting, but the advancement of psychedelic medicine gives me hope. It’s clear from this report that people are ready and willing to explore psychedelics as powerful tools to improve their mental health, and against the backdrop of the mental health crisis, it’s no wonder why: last-generation mental health treatments aren’t getting the job done, and it has become impossible to ignore the mountain of studies demonstrating the remarkable effectiveness of ketamine, MDMA, psilocybin, and more.

Mindbloom is committed to expanding access to safe and effective psychedelic medicine – starting with at-home ketamine therapy, and the new pathways we’re launching for issues like grief, managing emotions, and rewiring habits. This treatment is transforming lives today, and, with FDA approval of MDMA and psilocybin coming soon, the future of mental health care looks bright. 

Click here to view the full report, and please contact press@mindbloom.com with any inquiries.